[基于 RNA 的 NGS 检测到一例 EML4-ALK 融合 V1 亚型肺腺癌】。]

Q4 Medicine
Yue Xu, Ning Mu, Mei Liu, Shengnan Wu, Chunhua Ma
{"title":"[基于 RNA 的 NGS 检测到一例 EML4-ALK 融合 V1 亚型肺腺癌】。]","authors":"Yue Xu, Ning Mu, Mei Liu, Shengnan Wu, Chunhua Ma","doi":"10.3779/j.issn.1009-3419.2024.102.23","DOIUrl":null,"url":null,"abstract":"<p><p>Lung cancer is the malignant tumor with the highest incidence and mortality rate worldwide. For lung adenocarcinoma, identifying specific gene mutations, fusions, and giving corresponding targeted drugs can greatly improve the survival time of the patients. Among them, anaplastic lymphoma kinase (ALK) fusion occurs in 3%-7% of non-small cell lung cancer (NSCLC). In clinical practice, a variety of detection methods can be used to determine the ALK fusion status, but false negative test results are possible. This paper retrospectively analyzed the diagnosis and treatment of a patient with lung adenocarcinoma, judged the ALK fusion status by various detection methods. Among them, immunohistochemistry (IHC)(Ventana D5F3), RNA based next-generation sequencing (RNA-based NGS) confirmed positive echinoderm microtubule associated protein like 4 (EML4)-ALK fusion, while DNA-based NGS was negative. This paper analyzed the detection methods of ALK fusion, in order to clarify which detection method is the most accurate and simple to choose in different clinical cases and guide the subsequent treatment.\u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"27 6","pages":"480-484"},"PeriodicalIF":0.0000,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11258648/pdf/","citationCount":"0","resultStr":"{\"title\":\"[A Case of EML4-ALK Fusion V1 Subtype Lung Adenocarcinoma \\u2029Detected by RNA-based NGS].\",\"authors\":\"Yue Xu, Ning Mu, Mei Liu, Shengnan Wu, Chunhua Ma\",\"doi\":\"10.3779/j.issn.1009-3419.2024.102.23\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Lung cancer is the malignant tumor with the highest incidence and mortality rate worldwide. For lung adenocarcinoma, identifying specific gene mutations, fusions, and giving corresponding targeted drugs can greatly improve the survival time of the patients. Among them, anaplastic lymphoma kinase (ALK) fusion occurs in 3%-7% of non-small cell lung cancer (NSCLC). In clinical practice, a variety of detection methods can be used to determine the ALK fusion status, but false negative test results are possible. This paper retrospectively analyzed the diagnosis and treatment of a patient with lung adenocarcinoma, judged the ALK fusion status by various detection methods. Among them, immunohistochemistry (IHC)(Ventana D5F3), RNA based next-generation sequencing (RNA-based NGS) confirmed positive echinoderm microtubule associated protein like 4 (EML4)-ALK fusion, while DNA-based NGS was negative. This paper analyzed the detection methods of ALK fusion, in order to clarify which detection method is the most accurate and simple to choose in different clinical cases and guide the subsequent treatment.\\u2029.</p>\",\"PeriodicalId\":39317,\"journal\":{\"name\":\"中国肺癌杂志\",\"volume\":\"27 6\",\"pages\":\"480-484\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-06-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11258648/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"中国肺癌杂志\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3779/j.issn.1009-3419.2024.102.23\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国肺癌杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3779/j.issn.1009-3419.2024.102.23","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

肺癌是全球发病率和死亡率最高的恶性肿瘤。对于肺腺癌,识别特定的基因突变、融合,并给予相应的靶向药物,可以大大提高患者的生存时间。其中,无性淋巴瘤激酶(ALK)融合发生在3%-7%的非小细胞肺癌(NSCLC)中。在临床实践中,有多种检测方法可用于确定ALK融合状态,但也可能出现假阴性检测结果。本文回顾性分析了一名肺腺癌患者的诊断和治疗,通过多种检测方法判断ALK融合状态。其中,免疫组化(IHC)(Ventana D5F3)、基于RNA的新一代测序(RNA-based NGS)证实棘皮微管相关蛋白样4(EML4)-ALK融合为阳性,而基于DNA的NGS为阴性。本文对ALK融合的检测方法进行了分析,以期明确在不同临床病例中选择哪种检测方法最准确、最简便,并指导后续治疗。.
本文章由计算机程序翻译,如有差异,请以英文原文为准。
[A Case of EML4-ALK Fusion V1 Subtype Lung Adenocarcinoma 
Detected by RNA-based NGS].

Lung cancer is the malignant tumor with the highest incidence and mortality rate worldwide. For lung adenocarcinoma, identifying specific gene mutations, fusions, and giving corresponding targeted drugs can greatly improve the survival time of the patients. Among them, anaplastic lymphoma kinase (ALK) fusion occurs in 3%-7% of non-small cell lung cancer (NSCLC). In clinical practice, a variety of detection methods can be used to determine the ALK fusion status, but false negative test results are possible. This paper retrospectively analyzed the diagnosis and treatment of a patient with lung adenocarcinoma, judged the ALK fusion status by various detection methods. Among them, immunohistochemistry (IHC)(Ventana D5F3), RNA based next-generation sequencing (RNA-based NGS) confirmed positive echinoderm microtubule associated protein like 4 (EML4)-ALK fusion, while DNA-based NGS was negative. This paper analyzed the detection methods of ALK fusion, in order to clarify which detection method is the most accurate and simple to choose in different clinical cases and guide the subsequent treatment.
.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
中国肺癌杂志
中国肺癌杂志 Medicine-Pulmonary and Respiratory Medicine
CiteScore
1.40
自引率
0.00%
发文量
5131
审稿时长
14 weeks
期刊介绍: Chinese Journal of Lung Cancer(CJLC, pISSN 1009-3419, eISSN 1999-6187), a monthly Open Access journal, is hosted by Chinese Anti-Cancer Association, Chinese Antituberculosis Association, Tianjin Medical University General Hospital. CJLC was indexed in DOAJ, EMBASE/SCOPUS, Chemical Abstract(CA), CSA-Biological Science, HINARI, EBSCO-CINAHL,CABI Abstract, Global Health, CNKI, etc. Editor-in-Chief: Professor Qinghua ZHOU.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信